Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li, Nanxin
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. [electronic resource] - Current medical research and opinion 2016 - 385-94 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
1473-4877
10.1185/03007995.2015.1130691 doi
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Breast Neoplasms--drug therapy
Capecitabine--administration & dosage
Everolimus--administration & dosage
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Postmenopause
Proportional Hazards Models
Receptor, ErbB-2
Retrospective Studies
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. [electronic resource] - Current medical research and opinion 2016 - 385-94 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
1473-4877
10.1185/03007995.2015.1130691 doi
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Breast Neoplasms--drug therapy
Capecitabine--administration & dosage
Everolimus--administration & dosage
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Postmenopause
Proportional Hazards Models
Receptor, ErbB-2
Retrospective Studies